These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6114006)

  • 1. Insulin and glucagon breakthrough of somatostatin suppression: importance of portal vein hormone measurements.
    Polonsky K; Jaspan J; Pugh W; Dhorajiwala J; Abraham M; Blix P; Moossa AR
    Diabetes; 1981 Aug; 30(8):664-9. PubMed ID: 6114006
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of somatostatin on neurotensin-induced glucagon release and hyperglycemia.
    Ukai M; Inoue I; Itatsu T
    Endocrinology; 1977 May; 100(5):1284-6. PubMed ID: 849724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of somatostatin on the hepatic extraction of insulin and glucagon in the anesthetized dog.
    Ishida T; Röjdmark S; Bloom G; Chou MC; Field JB
    Endocrinology; 1980 Jan; 106(1):220-30. PubMed ID: 7349954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evanescent effects of hypo- and hyperglucagonemia on blood glucose homeostasis.
    Sherwin R; Wahren J; Felig P
    Metabolism; 1976 Nov; 25(11 Suppl 1):1381-3. PubMed ID: 979638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogs with selected biologic activities.
    Brown M; Rivier J; Vale W
    Metabolism; 1976 Nov; 25(11 Suppl 1):1501-3. PubMed ID: 979656
    [No Abstract]   [Full Text] [Related]  

  • 6. Pancreatic innervation is not essential for exercise-induced changes in glucagon and insulin or glucose kinetics.
    Coker RH; Koyama Y; Lacy DB; Williams PE; Rhèaume N; Wasserman DH
    Am J Physiol; 1999 Dec; 277(6):E1122-9. PubMed ID: 10600803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude of negative arterial-portal glucose gradient alters net hepatic glucose balance in conscious dogs.
    Pagliassotti MJ; Myers SR; Moore MC; Neal DW; Cherrington AD
    Diabetes; 1991 Dec; 40(12):1659-68. PubMed ID: 1684554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake.
    Galassetti P; Shiota M; Zinker BA; Wasserman DH; Cherrington AD
    Am J Physiol; 1998 Jul; 275(1):E101-11. PubMed ID: 9688880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise-induced rise in glucagon and ketogenesis during prolonged muscular work.
    Wasserman DH; Spalding JA; Bracy D; Lacy DB; Cherrington AD
    Diabetes; 1989 Jun; 38(6):799-807. PubMed ID: 2566546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
    Sherwin RS; Hendler R; DeFronzo R; Wahren J; Felic P
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):348-52. PubMed ID: 264686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog.
    Sindelar DK; Balcom JH; Chu CA; Neal DW; Cherrington AD
    Diabetes; 1996 Nov; 45(11):1594-604. PubMed ID: 8866566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged suppression of pituitary and pancreatic hormone release by a somatostatin analog.
    Lien EL; Fenichel RL; Grant NH; Boxill GC; Greenwood J; Yardley JP
    Biochem Biophys Res Commun; 1977 Aug; 77(4):1317-25. PubMed ID: 143285
    [No Abstract]   [Full Text] [Related]  

  • 13. Interaction of somatostatin, glucagon, and insulin on hepatic glucose output in the normal dog.
    Altszuler N; Gottlieb B; Hampshire J
    Diabetes; 1976 Feb; 25(2):116-21. PubMed ID: 1248672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery.
    Holste LC; Connolly CC; Moore MC; Neal DW; Cherrington AD
    Am J Physiol; 1997 Sep; 273(3 Pt 1):E488-96. PubMed ID: 9316437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapancreatic effect of somatostatin infusion to increase glucose clearance.
    Bergman RN; Ader M; Finegood DT; Pacini G
    Am J Physiol; 1984 Sep; 247(3 Pt 1):E370-9. PubMed ID: 6148014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of stable metabolic conditions during islet suppression in dogs.
    Bradley DC; Bergman RN
    Am J Physiol; 1992 Apr; 262(4 Pt 1):E532-8. PubMed ID: 1348903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.
    Mittelman SD; Fu YY; Rebrin K; Steil G; Bergman RN
    J Clin Invest; 1997 Dec; 100(12):3121-30. PubMed ID: 9399959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of somatostatin (SRIF) infusion on glucose homeostasis in newborn lambs: evidence for a significant role of glucagon.
    Sperling MA; Grajwer L; Leake RD; Fisher DA
    Pediatr Res; 1977 Sep; 11(9 Pt 1):962-7. PubMed ID: 904983
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of beta-endorphin on biogenic amines, insulin, and glucagon levels in the hepatic portal circulation of normal and pancreatectomized dogs.
    Hussain MN; Kikuchi K; Cukerman E; Sirek A; Sirek OV
    Endocrinology; 1986 Aug; 119(2):685-90. PubMed ID: 2942391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of selective insulin or glucagon deficiency on glucose turnover.
    Lickley HL; Ross GG; Vranic M
    Am J Physiol; 1979 Mar; 236(3):E255-62. PubMed ID: 426056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.